Patents by Inventor Lloyd H. Kasper

Lloyd H. Kasper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
    Patent number: 9625473
    Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-? concentration, IL-2 concentration and IFN-? concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: April 18, 2017
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Lloyd H. Kasper, Jacqueline Y. Smith
  • Nutraceutical Composition And Methods For Prevention Or Treating Multiple Sclerosis
    Publication number: 20160158269
    Abstract: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 9, 2016
    Inventors: Lloyd H. Kasper, Javier Ochoa-Reparaz
  • NUTRACEUTICAL COMPOSITION AND METHODS FOR PREVENTING OR TREATING MULTIPLE SCLEROSIS
    Publication number: 20160143941
    Abstract: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
    Type: Application
    Filed: December 14, 2015
    Publication date: May 26, 2016
    Applicant: Trustees of Dartmouth College
    Inventors: Lloyd H. Kasper, Javier Ochoa-Reparaz
  • CYTOKINE BIOMARKERS AS PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE FOR GLATIRAMER ACETATE
    Publication number: 20150241446
    Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-? concentration, IL-2 concentration and IFN-? concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.
    Type: Application
    Filed: May 7, 2015
    Publication date: August 27, 2015
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventors: Lloyd H. Kasper, Jacqueline Y. Smith
  • Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
    Patent number: 9063153
    Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-? concentration, IL-2 concentration and IFN-? concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: June 23, 2015
    Assignee: TEVA PHARMACEUTICALS INDUSTRIES LTD.
    Inventors: Lloyd H. Kasper, Jacqueline Y. Smith
  • CYTOKINE BIOMARKERS AS PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE FOR GLATIRAMER ACETATE
    Publication number: 20140294899
    Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-? concentration, IL-2 concentration and IFN-? concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 2, 2014
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Lloyd H. Kasper, Jacqueline Y. Smith
  • Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
    Patent number: 8709433
    Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-? concentration, IL-2 concentration and IFN-? concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: April 29, 2014
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Lloyd H. Kasper, Jacqueline Y. Smith
  • METHOD FOR STIMULATING FOXP3+ REGULATORY T CELL EXPRESSION OF CD39
    Publication number: 20140030807
    Abstract: Disclosed is the use of isolated Bacteroides fragilis capsular polysaccharide A in a method for stimulating FoxP3+ regulatory T cell expression of CD39.
    Type: Application
    Filed: July 19, 2011
    Publication date: January 30, 2014
    Applicant: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Lloyd H. Kasper, Javier Ochoa-Reparaz
  • Prevention or treatment of immune-relevant disease by modification of microfloral populations
    Patent number: 8586029
    Abstract: The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: November 19, 2013
    Assignee: Trustees of Dartmouth College
    Inventors: Lloyd H. Kasper, Javier Ochoa-Repáraz
  • Nutraceutical composition and methods for preventing or treating multiple sclerosis
    Patent number: 8580278
    Abstract: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: November 12, 2013
    Assignee: Trustees of Dartmouth College
    Inventors: Lloyd H. Kasper, Javier Ochoa-Reparaz
  • CYTOKINE BIOMARKERS AS PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE FOR GLATIRAMER ACETATE
    Publication number: 20120121619
    Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-? concentration, IL-2 concentration and IFN-? concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.
    Type: Application
    Filed: October 10, 2011
    Publication date: May 17, 2012
    Inventors: Lloyd H. Kasper, Jacqueline Y. Smith
  • Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis
    Publication number: 20120094950
    Abstract: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
    Type: Application
    Filed: June 17, 2011
    Publication date: April 19, 2012
    Applicant: Trustees of Dartmouth College
    Inventors: Lloyd H. Kasper, Javier Ochoa-Reparaz
  • Prevention or Treatment of Immune-Relevant Disease by Modification of Microfloral Populations
    Publication number: 20110086011
    Abstract: The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics.
    Type: Application
    Filed: June 3, 2009
    Publication date: April 14, 2011
    Inventors: Lloyd H. Kasper, Javier Ochoa-Repáraz
  • Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis
    Publication number: 20110009360
    Abstract: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
    Type: Application
    Filed: July 20, 2010
    Publication date: January 13, 2011
    Inventors: Lloyd H. Kasper, Javier Ochoa-Reparaz
  • Nutraceutical composition and methods for preventing or treating multiple sclerosis
    Publication number: 20100311686
    Abstract: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
    Type: Application
    Filed: November 3, 2009
    Publication date: December 9, 2010
    Inventors: Lloyd H. Kasper, Javier Ochoa-Reparaz
  • Method of augmenting T cell-mediated immunity against Toxoplasma gondii
    Patent number: 6399077
    Abstract: A method of augmenting T cell-mediated immunity against Toxoplasma gondii is provided. Immunization with Toxoplasma gondii soluble parasite antigen and exogenous rIL-15 was found to protect against Toxoplasma gondii infection.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: June 4, 2002
    Assignee: Trustees of Dartmouth College
    Inventors: Lloyd H. Kasper, Imtiaz A. Khan
  • METHOD OF AUGMENTING T CELL-MEDIATED IMMUNITY AGAINST TOXOPLASMA GONDII
    Publication number: 20020031519
    Abstract: A method of augmenting T cell-mediated immunity against Toxoplasma gondii is provided. Immunization with Toxoplasma gondii soluble parasite antigen and exogenous rIL-15 was found to protect against Toxoplasma gondii infection.
    Type: Application
    Filed: May 19, 1999
    Publication date: March 14, 2002
    Inventors: LLOYD H. KASPER, IMTIAZ A. KHAN
  • P30 peptides of Toxoplasma gondii
    Patent number: 5859196
    Abstract: Genetic material encoding p30 and B1 peptides of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 12, 1999
    Assignees: Trustees of the Leland Stanford Junior University, Trustees of Dartmouth College
    Inventors: John Charles Boothroyd, James Lawrence Burg, Lloyd H. Kasper
  • Diagnostic genes for toxoplasmosis
    Patent number: 5629414
    Abstract: Genetic material encoding p30 and B1 peptides of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: May 13, 1997
    Assignee: The Board of Trustees of the Leeland Stanford Junior University
    Inventors: John C. Boothroyd, James L. Burg, Lloyd H. Kasper